Novel approaches for preventing or limiting events (Naples) III trial: Randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting

JACC: Cardiovascular Interventions

Volumn 8, Issue 3, 2015, Pages 414-423

  Briguori, Carlo ^a   Visconti, Gabriella ^a   Focaccio, Amelia ^a   Donahue, Michael ^a   Golia, Bruno ^a   Selvetella, Lucio ^a   Ricciardelli, Bruno ^a  

^a Unit of Reproductive Medicine   (Italy)

Author keywords

anticoagulant; bivalirudin; bleeding; heparin; percutaneous coronary intervention

Indexed keywords

BIOLOGICAL MARKER; HEPARIN; HIRULOG; HIRUDIN DERIVATIVE; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

ADULT; AGED; ARTICLE; BLEEDING; CONTROLLED STUDY; CORONARY STENTING; DEATH; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; STENT THROMBOSIS; SURGICAL APPROACH; TRANSFEMORAL ELECTIVE PERCUTANEOUS CORONARY INTERVENTION; VASCULAR ACCESS; ADVERSE EFFECTS; CHEMICALLY INDUCED; COMPARATIVE STUDY; CORONARY ARTERY DISEASE; DEVICES; FEMORAL ARTERY; ITALY; PROCEDURES; PROSPECTIVE STUDY; PUNCTURE; RISK FACTOR; TIME; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; DOUBLE-BLIND METHOD; FEMALE; FEMORAL ARTERY; HEMORRHAGE; HEPARIN; HIRUDINS; HUMANS; ITALY; MALE; PEPTIDE FRAGMENTS; PERCUTANEOUS CORONARY INTERVENTION; PROSPECTIVE STUDIES; PUNCTURES; RECOMBINANT PROTEINS; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84926415694     PISSN: 19368798     EISSN: 18767605     Source Type: Journal    
DOI: 10.1016/j.jcin.2014.10.015     Document Type: Article

References (35)

1. G.N. Levine, E.R. Bates, and J.C. Blankenship 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions J Am Coll Cardiol 58 2011 e44 e122
2. W. Wijns, P. Kolh, N. Danchin for the Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery, the European Association for Percutaneous Cardiovascular Interventions Guidelines on myocardial revascularization Eur Heart J 31 2010 2501 2555
3. J.W. Eikelboom, S.R. Mehta, S.S. Anand, C. Xie, K.A. Fox, and S. Yusuf Adverse impact of bleeding on prognosis in patients with acute coronary syndromes Circulation 114 2006 774 782
4. F. Feit, M.D. Voeltz, and M.J. Attubato Predictors and impact of major hemorrhage on mortality following percutaneous coronary intervention from the REPLACE-2 trial Am J Cardiol 100 2007 1364 1369
5. S.V. Manoukian, F. Feit, and R. Mehran Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the acuity trial J Am Coll Cardiol 49 2007 1362 1368
6. G. Ndrepepa, P.B. Berger, and J. Mehilli Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point J Am Coll Cardiol 51 2008 690 697
7. E. Young, M. Prins, M.N. Levine, and J. Hirsh Heparin binding to plasma proteins, an important mechanism for heparin resistance Thromb Haemost 67 1992 639 643
8. M. Sobel, W.R. Fish, and N. Toma Heparin modulates integrin function in human platelets J Vasc Surg 33 2001 587 594
9. G.W. Stone, J.H. Ware, M.E. Bertrand for the ACUITY Investigators Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial JAMA 298 2007 2497 2506
10. G.W. Stone, B. Witzenbichler, G. Guagliumi for the HORIZONS-AMI Trial Investigators Bivalirudin during primary PCI in acute myocardial infarction N Engl J Med 358 2008 2218 2230
11. A.M. Lincoff, J.A. Bittl, R.A. Harrington for the REPLACE-2 Investigators Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial JAMA 289 2003 853 863
12. R. Mehran, A.J. Lansky, B. Witzenbichler for the HORIZONS-AMI Trial Investigators Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial Lancet 374 2009 1149 1159
13. P.G. Steg, A. van 't Hof, C.W. Hamm for the EUROMAX Investigators Bivalirudin started during emergency transport for primary PCI N Engl J Med 369 2013 2207 2217
14. A. Kastrati, F.J. Neumann, J. Mehilli for the ISAR-REACT 3 Trial Investigators Bivalirudin versus unfractionated heparin during percutaneous coronary intervention N Engl J Med 359 2008 688 696
15. S. Schulz, J. Mehilli, G. Ndrepepa for the ISAR-REACT 3 Trial Investigators Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial Eur Heart J 31 2010 582 587
16. C. Briguori, G. Visconti, and A. Focaccio Novel Approaches for Preventing or Limiting Events (NAPLES III) trial: randomised comparison of bivalirudin versus unfractionated heparin in patients at high risk of bleeding undergoing elective coronary stenting through the femoral approach: rationale and design Cardiovasc Drug Ther 28 2014 273 279
17. E. Nikolsky, R. Mehran, and G. Dangas Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach Eur Heart J 28 2007 1936 1945
18. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
19. M.S. Sabatine, D.A. Morrow, and R.P. Giugliano Association of hemoglobin levels with clinical outcomes in acute coronary syndromes Circulation 111 2005 2042 2049
20. S. Schulman, C. Kearon Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients J Thromb Haemost 3 2005 692 694
21. E.G. Bovill, M.L. Terrin, and D.C. Stump Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis In Myocardial Infarction (TIMI), phase II trial Ann Intern Med 115 1991 256 265
22. K. Thygesen, J.S. Alpert, A.S. Jaffe for the Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction Third universal definition of myocardial infarction J Am Coll Cardiol 60 2012 1581 1598
23. D.E. Cutlip, S. Windecker, R. Mehran for the Academic Research Consortium Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
24. S.V. Rao, L.A. McCoy, and J.A. Spertus An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: a report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry J Am Coll Cardiol Intv 6 2013 897 904
25. S.K. Mehta, A.D. Frutkin, J.B. Lindsey for the National Cardiovascular Data Registry Bleeding in patients undergoing percutaneous coronary intervention: the development of a clinical risk algorithm from the National Cardiovascular Data Registry Circ Cardiovasc Interv 2 2009 222 229
26. J.A. Bittl, J. Strony, J.A. Brinker for the Hirulog Angioplasty Study Investigators Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina N Engl J Med 333 1995 764 769
27. A.M. Lincoff, J.A. Bittl, N.S. Kleiman for the REPLACE-1 Investigators Comparison of bivalirudin versus heparin during percutaneous coronary intervention (the Randomized Evaluation of PCI Linking Angiomax to Reduced Clinical Events [REPLACE-1] trial) Am J Cardiol 93 2004 1092 1096
28. G. Patti, V. Pasceri, and L. D'Antonio Comparison of safety and efficacy of bivalirudin versus unfractionated heparin in high-risk patients undergoing percutaneous coronary intervention (from the Anti-Thrombotic Strategy for Reduction of Myocardial Damage During Angioplasty-Bivalirudin vs Heparin study) Am J Cardiol 110 2012 478 484
29. G. Tarantini, S.J. Brener, and A. Barioli Impact of baseline hemorrhagic risk on the benefit of bivalirudin versus unfractionated heparin in patients treated with coronary angioplasty: a meta-regression analysis of randomized trials Am Heart J 167 2014 401 412.e6
30. A.P. Amin, S.P. Marso, and S.V. Rao Cost-effectiveness of targeting patients undergoing percutaneous coronary intervention for therapy with bivalirudin versus heparin monotherapy according to predicted risk of bleeding Circ Cardiovasc Qual Outcomes 3 2010 358 365
31. S.V. Rao, K. O'Grady, and K.S. Pieper A comparison of the clinical impact of bleeding measured by two different classifications among patients with acute coronary syndromes J Am Coll Cardiol 47 2006 809 816
32. S.S. Jolly, S. Amlani, M. Hamon, S. Yusuf, and S.R. Mehta Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials Am Heart J 157 2009 132 140
33. C.N. Hess, S.V. Rao, and D.F. Kong Embedding a randomized clinical trial into an ongoing registry infrastructure: unique opportunities for efficiency in design of the Study of Access Site for Enhancement of Percutaneous Coronary Intervention for Women (SAFE-PCI for Women) Am Heart J 166 2013 421 428
34. M. Valgimigli, P. Calabro, B. Cortese for the MATRIX Investigators Scientific foundation and possible implications for practice of the Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox (MATRIX) trial J Cardiovasc Transl Res 7 2014 101 111
35. R. Mehran, S.J. Pocock, and E. Nikolsky A risk score to predict bleeding in patients with acute coronary syndromes J Am Coll Cardiol 55 2010 2556 2566